Click here for slides on this topic


ACS

Abbreviation for acute coronary syndrome, any constellation of symptoms attributed to obstruction of the coronary arteries.
The following content matched the glossary term: ACS

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus

Top

Lincoff AM, Tardiff J-C, Schwartz GG, et al; for the AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus. The AleCardio randomized clinical trial. JAMA.. 2014. doi:10.1001/jama.2014.3321.

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Top

White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 - No Pancreatic Risk in DPP-4 Cardiovascular Safety Studies

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

 

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

OnsiteInsight November 2012

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council

Top

Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P; American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.. Circulation. 2008;117(12):1610-9. Hyperglycemia is common and associated with markedly increased mortality rates in patients hospitalized with acute coronary syndromes (ACS). Despite the fact that several studies have documented this association, hyperglycemia remains underappreciated as a risk factor, and it is frequently untreated in ACS patients.

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients w type 2 diabetes & previous myocardial infarction: from PROactive Study

Top

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772-80. This analysis from the PROactive (PROspective pioglitAzone macroVascular Events) study assesses the effects of pioglitazone on mortality and macrovascular morbidity in patients with type 2 diabetes and a previous myocardial infarction (MI).

1 2 Next 

Slide Library Results

Search Results for: ACS Slides Found: 29
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
Odds Ratios of In-Hospital Mortality by Admission and Fasting Glucose Levels
Mortality Risk Up to 6-Months in Patients With or Without Diabetes
PROactive 10 Substudy: Time to First Event from MACE Endpoint
AIM-HIGH: Design
AIM-HIGH: Rate of the Primary Endpoint
AIM-HIGH: Rate of Secondary Endpoints
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
AleCardio: Time to First Occurrence of Any Part of the Composite of CV Mortality, Nonfatal MI, or Nonfatal Stroke With Aleglitazar Vs Placebo
AleCardio: Aleglitazar Safety Vs Placebo
AleCardio: Design
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
CHAMPION PHOENIX: Baseline Characteristics
CHAMPION PHOENIX: Ischemic Endpoints
CHAMPION PHOENIX: Randomization
Platelet Inhibition During Percutaneous Coronary Intervention
ACCELERATE CETP Inhibitor Trial Ended Early Due to Futility
Antiplatelet Therapy Recommendations ADA Guidelines | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
Combination Statin Therapy in Type 2 Diabetes ADA Guidelines | NDEI PPT